<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849511</url>
  </required_header>
  <id_info>
    <org_study_id>270472</org_study_id>
    <nct_id>NCT00849511</nct_id>
  </id_info>
  <brief_title>Melatonin for Migraine Prevention</brief_title>
  <acronym>MMP</acronym>
  <official_title>Melatonin for Migraine Prevention (The MMP-study): A Randomized, Double-blind, Cross-over, Placebo-controlled Study of Melatonin in Prophylactic Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tromso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordlandssykehuset HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The circadian system with its centre in the hypothalamus is involved in migraine
      pathophysiology. Whether it plays a pivotal role is not clarified. The investigators
      postulate that a destabilized circadian system may increase migraine attack susceptibility,
      and that stabilization by supplying melatonin a migraine preventive effect will be achieved.

      A previous open label study has shown effects that certainly warrant a placebo controlled
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Migraine attack frequency</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night time sleep quality</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Point prevalence of insomnia</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo 8 weeks, 6 weeks washout, extended-release melatonin 2 mg vesper for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extended-release melatonin 2 mg vesper for 8 weeks, 6 weeks washout, placebo 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks</description>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_label>Melatonin first</arm_group_label>
    <other_name>Circadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 65 years, both male and females.

          -  Migraine present for at least 1 year and fulfilling diagnostic criteria that conform
             to those of the International Headache Society (HIS) [2] but otherwise healthy.

          -  Attacks of migraine should occur 4-6 times per month, there should be no regular use
             of other drugs, and the patient has to be able to differentiate between migraine
             headache and non-migrainous headache.

          -  Preventive drugs for migraine should not have been used the last three months.

          -  Conventional acute attack treatment is accepted, but not sporadic use of other drugs
             like hypnotics and anxiolytics.

          -  Residence of North-Norway.

        Exclusion Criteria:

          -  Medication overuse headache, chronic migraine.

          -  Pregnant and breast feeding women.

          -  Patient with either serious co-morbidity or conditions requiring medical treatment or
             caution.

          -  Psychiatric disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Departement of Neurology, NLSH HF</name>
      <address>
        <city>Bodø</city>
        <zip>8092</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology</name>
      <address>
        <city>Tromsø</city>
        <zip>9037</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004 Aug 24;63(4):757.</citation>
    <PMID>15326268</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nordlandssykehuset HF</investigator_affiliation>
    <investigator_full_name>Karl B. Alstadhaug</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Migraine prevention</keyword>
  <keyword>Crossover</keyword>
  <keyword>Melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

